Dasamia 20, 50, 70 & 100 20 mg, 50 mg, 70 mg & 100 mg Tablet
PDF Leaflet Revision Date: 15 Aug 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adults with Ph+ CML and Ph+ ALL.
Dosage (summary)
Chronic phase CML: 100 mg once daily; Advanced phase CML/Ph+ ALL: 70 mg twice daily.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Not recommended during pregnancy; potential for fetal harm. Avoid breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP3A4 inducers
- H2 antagonists
- Proton pump inhibitors
Contraindications
- Hypersensitivity to dasatinib
- Concomitant use of H2 antagonists or proton pump inhibitors
Common side effects
- Myelosuppression
- Thrombocytopenia
- Fluid retention
- CNS bleeding
Counselling Points
- Take consistently with or without food
- Monitor for signs of bleeding
- Use contraception
- Report any severe side effects
Serious warnings
- Severe bleeding events
- Cardiac adverse reactions
- Pulmonary arterial hypertension
- QT prolongation
Important Disclaimer
The Dasamia 20, 50, 70 & 100 20 mg, 50 mg, 70 mg & 100 mg Tablet professional information leaflet below is the property of Ranbaxy Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
